Physician profile
Satinder Kaur
NPI 1689851495
$3,661.54
in general payments reported to CMS, 2019-2025
13 companies · $16.28 in 2025
The $16.28 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $103 · 2021: $38.30 · 2022: $1,549 · 2023: $1,664 · 2024: $93.89 · 2025: $16.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,375 · Food and Beverage: $399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,375.00 |
| Food and Beverage | $399.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $2,797.86 | 2022-2023 | Nexplanon, Hadlima |
| Aspira Women'S Health INC | $355.16 | 2022-2024 | Ova1 |
| Abbvie INC. | $210.29 | 2019-2023 | |
| Hologic Sales and Service, LLC | $77.34 | 2020-2022 | |
| Covidien LP | $49.62 | 2019 | |
| Travere Therapeutics, INC. | $37.01 | 2023 | |
| Pfizer INC. | $36.92 | 2020-2025 | |
| Qiagen, LLC | $17.46 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $17.00 | 2022 | |
| Glaxosmithkline, LLC. | $16.78 | 2019 | |
| Coloplast Corp | $16.14 | 2024 | |
| Alnylam Pharmaceuticals INC. | $15.63 | 2023 | Givlaari |
| Merck Sharp & Dohme LLC | $14.33 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satinder Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.